Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350873 | 0.82 | EPHX1 (0.40) | TRPV1EPHX1ALOX15NAAAEPHX2 | |
| SCHEMBL4346130 | 0.80 | CA1 (0.51) | TRPV1EPHX1NAAAEPHX2CA1 | |
| SCHEMBL4348991 | 0.79 | NAAA (0.52) | TRPV1ALOX15NAAAAPP | |
| SCHEMBL4345395 | 0.79 | CA1 (0.49) | TRPV1ALOX15CA1CA2ALDH1A1 | |
| SCHEMBL4348855 | 0.77 | EPHX1 (0.36) | TRPV1EPHX1ALOX15NAAAEPHX2 | |
| SCHEMBL4356038 | 0.77 | HPGD (0.44) | TRPV1EPHX1NAAAEPHX2ALDH1A1 | |
| SCHEMBL4358550 | 0.75 | EPHX2 (0.39) | TRPV1EPHX1NAAAEPHX2CA1 | |
| SCHEMBL4348484 | 0.75 | EPHX2 (0.43) | TRPV1EPHX1NAAAEPHX2CA1 | |
| SCHEMBL4355852 | 0.74 | EPHX2 (0.48) | TRPV1EPHX1NAAAEPHX2ALDH1A1 | |
| SCHEMBL4350102 | 0.74 | TRPV1 (0.49) | TRPV1NAAAEPHX2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | TRPV1 2328/4885EPHX1 1676/4885ALOX15 2259/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | TRPV1 2320/4885EPHX1 1334/4885ALOX15 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.